Tag Archive for: blood cancer drug

The company’s new anemia drug Reblozyl and its already off patent blood cancer drug Revlimid outperformed Wall Street forecasts.

Last November Blenrep failed to meet the main goal in a late-stage study that was designed to show it was better than an existing treatment on the market, leading GSK to stop selling the drug in the United States.

The company is testing Carvykti in multiple myeloma patients, with a history of relapse, who have stopped responding to existing treatment and have received one to three prior therapies.